Diabetes Research and Clinical Practice
Volume 88, Issue 1 , Pages 71-75 , April 2010

Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

  • Dan-yan Xu

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China
    • Corresponding Author InformationCorresponding author at: Department of Cardiology, Internal Medicine, Second Xiangya Hospital, 139 Middle Renming Road, Changsha, Hunan 410011, PR China. Tel.: +86 731 5292100; fax: +86 731 4895989.
    • ,
  • Shui-Ping Zhao

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China
    • ,
  • Qiu-xia Huang

      Affiliations

    • Department of Endocrinology, The People's Hospital of Dongguan City, Dongguan, Guangdong, 523018, PR China
    • ,
  • Wei Du

      Affiliations

    • Department of Endocrinology, The People's Hospital of Dongguan City, Dongguan, Guangdong, 523018, PR China
    • ,
  • Yu-hua Liu

      Affiliations

    • Department of Endocrinology, The People's Hospital of Dongguan City, Dongguan, Guangdong, 523018, PR China
    • ,
  • Ling Liu

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China
    • ,
  • Xiao-mei Xie

      Affiliations

    • Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha, 410011, PR China

Received 20 September 2007 ,Revised 10 July 2009 ,Accepted 8 December 2009.

References 

  1. Dedoussis GV, Kaliora AC, Panagiotakos DB. Genes, diet and type 2 diabetes mellitus: a review. Rev. Diabet. Stud. 2007;4(Spring (1)):13–24
  2. Reusch JE, Draznin BB. Atherosclerosis in diabetes and insulin resistance. Diabetes Obes. Metab. 2007;9(July (4)):455–463
  3. Meigs JB, Nathan DM, D’Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care. 2002;25:1845–1850
  4. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. The Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation. 2007;(June):
  5. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 2007;167(June (11)):1145–1151
  6. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J. Am. Coll. Cardiol. 2007;49(May (21)):2112–2119
  7. Godi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr. Diab. Rep. 2007;7(June (3)):228–234
  8. Howard BV. Lipoprotein metabolism in diabetes mellitus. J. Lipid Res. 1987;28:613–628
  9. PyOrft UK, Laakso M, Uusltupa M. Diabetes and atherosclerosis: an epktemtologic view. Diabetes/Metab. Rev. 1987;2:464–524
  10. Sharma SC. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in juvenile onset and maturity onset diabetes mellitus. J. Pathol. 1981;4:501–503
  11. Festa A, D’Agostino R, Tracy RP, Haffner SM. Insulin Resistance Atherosclerosis Study. Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51:1131–1137
  12. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J. Diabetes Complicat. 2002;16:123–132
  13. Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002;25(Nov (11)):2065–2073
  14. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11(May (17)):1–144
  15. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:1607–1611
  16. Kabadi MU, Kabadi UM. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus[J]. Clin. Ther. 2004;26(1):63–69
  17. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects[J]. Diabetes Care. 2003;26(2):285–289
  18. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30(April (4)):790–794
  19. Jovanović D, Stojsić D, Zlatković M, Jović-Stosić J, Jovanović M. Bioequivalence assessment of the two brands of glimepiride tablets. Vojnosanit. Pregl. 2006;63(December (12)):1015–1020
  20. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol. Med. 2000;6:907–933
  21. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr. Med. Res. Opin. 2006;22(April (4)):751–759
  22. Draeger KE, Wernicke-Panten K, Lomp HJ, et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (amaryl): a double-blind comparison with glibenclamide. Horm. Metab. Res. 1996;28:419–425
  23. Suenson E, Petersen LC. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim. Biophys. Acta. 1986;870:510–519
  24. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 2007;May (12):2957–2966

PII: S0168-8227(09)00535-X

doi: 10.1016/j.diabres.2009.12.010

Diabetes Research and Clinical Practice
Volume 88, Issue 1 , Pages 71-75 , April 2010

Article Tools